{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:39:28Z","timestamp":1792481968514,"version":"4.5.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Acute anterior uveitis (AAU) is the most common extra\u2010musculoskeletal manifestation of axial spondyloarthritis (axSpA). This study compared the effect of the tumor necrosis factor inhibitor (TNFi) certolizumab pegol (CZP) with standard non\u2010biologic care, on AAU flare rate in patients with axSpA and high risk of recurrent uveitis flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>C\u2010VIEW (NCT03020992) was an open\u2010label, multicenter study in which patients with radiographic or non\u2010radiographic axSpA and high risk of uveitis flares received CZP for 96\u2009weeks. Here, AAU flare rate was compared between patients in C\u2010VIEW (up to 120\u2009weeks) and high\u2010risk patients with axSpA receiving standard non\u2010biologic treatment from the University of California, San Francisco (UCSF) and University Health Network Toronto Western Hospital (UHN). Overlap weighting (OW) was utilized to adjust for potential confounders, followed by Poisson regression to evaluate the effect of CZP on AAU flare rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty\u2010seven patients from C\u2010VIEW were compared to 75 axSpA patients with comparative disease activity and not on biologic treatment (UCSF\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940; UHN\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935). After OW, there were no significant differences between groups in baseline characteristics included in the model. The AAU flare rate was significantly lower for patients treated with CZP than in the comparator population: after OW, a 70.9% lower AAU flare rate was associated with CZP treatment (risk ratio [95% confidence interval]: 0.29 [0.18, 0.47];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study supports the findings of C\u2010VIEW and demonstrates the benefit of CZP over standard non\u2010biologic treatment as a promising therapeutic option in reducing AAU flares among high\u2010risk patients with axSpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1756-185x.70621","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:18:13Z","timestamp":1775042293000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non\u2010Biologic Treatment: Results From an Overlap Weighting Analysis in High\u2010Risk Patients With Axial Spondyloarthritis"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-4771","authenticated-orcid":false,"given":"Nigil","family":"Haroon","sequence":"first","affiliation":[{"name":"Department of Medicine\/Rheumatology, University Health Network, Schroeder Arthritis Institute University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Baskurt","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Chim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology University Health Network, Schroeder Arthritis Institute  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Inman","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology, University Health Network, Schroeder Arthritis Institute University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kumke","sequence":"additional","affiliation":[{"name":"UCB  Monheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Tham","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Kim","sequence":"additional","affiliation":[{"name":"UCB  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"van der Horst\u2010Bruinsma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Radboud University Medical Centre  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00486-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.08.017"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9460187"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22848"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex057"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20951733"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075754"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170115"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052092"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092585"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex174"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24025"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180312"},{"key":"e_1_2_10_16_1","first-page":"1759720x2110038","article-title":"Reduction of Anterior Uveitis Flares in Patients With Axial Spondyloarthritis on Certolizumab Pegol Treatment: Final 2\u2010Year Results From the Multicenter Phase IV C\u2010VIEW Study","volume":"13","author":"Horst\u2010Bruinsma I. E.","year":"2021","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131289"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.005"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"e_1_2_10_21_1","unstructured":"Food and Drug Administration \u201cCIMZIA (Certolizumab Pegol). Product Information \u201d(2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125160s275lbl.pdf."},{"key":"e_1_2_10_22_1","volume-title":"CIMZIA (Certolizumab Pegol). Summary of Product Characteristics","author":"European Medicines Agency","year":"2025"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00214-7"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30223"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The Impact of Certolizumab Pegol Treatment on the Incidence of Anterior Uveitis Flares in Patients With Axial Spondyloarthritis: 48\u2010Week Interim Results From C\u2010VIEW","volume":"6","author":"Horst\u2010Bruinsma I.","year":"2020","journal-title":"RMD Open"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.2016.1260466"},{"key":"e_1_2_10_27_1","unstructured":"N.Greifer \u201cWeightIt: Weighting for Covariate Balance in Observational Studies. R Package Version 1.3.0 \u201d(2024)."},{"key":"e_1_2_10_28_1","first-page":"250","article-title":"Addressing Extreme Propensity Scores via the Overlap Weights","volume":"188","author":"Li F.","year":"2018","journal-title":"American Journal of Epidemiology"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7819"},{"key":"e_1_2_10_30_1","unstructured":"N.Greifer \u201ccobalt: Covariate Balance Tables and Plots. R Package Version 4.5.5 \u201dhttps:\/\/CRAN.R\u2010project.org\/package=cobalt."},{"key":"e_1_2_10_31_1","unstructured":"N.Greifer \u201cCovariate Balance Tables and Plots: A Guide to theCobaltPackage \u201dhttps:\/\/cran.r\u2010project.org\/web\/packages\/cobalt\/vignettes\/cobalt.html."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10940-005-9000-9"},{"key":"e_1_2_10_33_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2018"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v111.i09"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq472"},{"key":"e_1_2_10_36_1","unstructured":"Estimating Effects After Weighting \u201cWeightIt: Weighting for Covariate Balance in Observational Studies Vignette Included in R Package WeightIt Version 1.3.0 \u201dhttps:\/\/cran.r\u2010project.org\/web\/packages\/WeightIt\/index.html."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2020.1731599"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02549-0"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185x.70621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185x.70621","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185x.70621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:56:13Z","timestamp":1792479373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185x.70621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/1756-185x.70621"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.70621","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70621"}}